Previous reports showed strong efficacy of anti-TIGIT antibodies in combination with anti-PD(L)1 agents in multiple tumor models, indicating a potential for TIGIT blocking antibodies as a combination partner for cancer treatment. This evidence concerns the gene CD274 and cancer.